ARCHIMED
Overview
ARCHIMED is a global private equity firm founded in 2014 and headquartered in Lyon, France, that focuses exclusively on the healthcare industries. The firm conducts growth buyout investments in small-cap and mid-cap healthcare companies across Europe, North America, and Asia. Its prioritized sectors include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, and MedTech.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Direct Healthcare Group | Feb 2026 | Buyout/LBO | Co-investor |
| Invacare Corporation | Jan 2026 | Buyout/LBO | Co-investor |
| Ark | Oct 2025 | Buyout/LBO | Lead |
| ARK Diagnostics, Inc. | Oct 2025 | Buyout/LBO | Lead |
| ExcellGene SA | Oct 2025 | Buyout/LBO | Lead |
Key People
Giuseppe Accogli
Chief Executive Officer
André-Michel Ballester
Managing Partner
Denis Ribon
Chairman - Managing Partner
Angie Kim
Managing Director
Rami Suzuki
Managing Director
Yuji Kato
Managing Director
Adrian Gilmore
Operating Partner
Alice Morillon
Operating Partner - Sustainability ESG Impact, Head of Sustainability & Impact
Andrew Frye
Operating Partner
Becky Karver-Rowe
Operating Partner
Benedikt von Braunmühl
Operating Partner
Brian Sheridan
Operating Partner
Christoph Boehmer
Operating Partner
DIDIER DARGENT
Operating Partner
Eric Dutang
Operating Partner
Gilles Guillemette
Operating Partner- Animal Health
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
